AbbVie Says It Will Present New Data Supporting Leading Gastroenterology Portfolio At 2024 Digestive Disease Week; Company To Present 15 Abstracts, Including Three Oral Presentations, In Crohn's Disease And Ulcerative Colitis
Portfolio Pulse from Benzinga Newsdesk
AbbVie will present new data supporting its gastroenterology portfolio at the 2024 Digestive Disease Week, including 15 abstracts and three oral presentations on Crohn's disease and ulcerative colitis. Key presentations will feature data from the SEQUENCE trial comparing SKYRIZI® and STELARA® in Crohn's disease, and efficacy and safety data from the INSPIRE and COMMAND Phase 3 studies of risankizumab for ulcerative colitis.
May 17, 2024 | 11:34 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
AbbVie will present significant new data on its gastroenterology portfolio at the 2024 Digestive Disease Week, including findings from the SEQUENCE trial comparing SKYRIZI® and STELARA® in Crohn's disease, and Phase 3 studies of risankizumab for ulcerative colitis.
The presentation of new data at a major medical conference is likely to positively impact AbbVie's stock in the short term, as it highlights advancements in their gastroenterology treatments, potentially leading to increased market confidence and future revenue growth.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100